 |
Breast
Cancer Metastasis to Bone
Breast cancer is the most common site of origin of metastatic deposits
in the skeleton. As many of half of all pathological fractures are
due to breast cancer. Although the prognosis for patients with breast
cancer that has spread to the bone vas poor in the past, nowadays these
patients are living much longer and feeling much better due to dramatic
improvements in medical and surgical treatments of this problem.
One of the most exiting new developments is a class of drugs knows as
bisphosphonates (Aredia, Fosamax, Didronel, and others). These drugs
have the ability to block the progression of tumor cells in the bone,
leading to dramatically fewer bone lesions and bone fractures in patients
with bone cancer who take them. Bisphosphonates may even stop the
spread of breast cancer to other organs, such as the liver or lungs, but
the reason for this is unknown. In the bones, the osteoclast cell
is stimulated by the cancer to break down and resorb bone matrix and calcium,
leading to pain and fractures. These drugs block the osteoclast
cells and keep the bones strong. I recommend all patients with breast
cancer take these drugs to protect their bones. Even if mild or
moderate side effects develop, such as joint aches or stomach upset, these
should be tolerated because protection of the bones is more important.
In my clinical experience, patients who go off these drugs because of
mild side effects have experienced rapid development of bone metastasis
and required surgery. Always consult your doctor about these treatments.
Pain is the most common presenting symptom. Pathological fracture
rarely occurs without a history of a few weeks or months of increasingly
severe pain. In some cases the patient has tried to ignore or deny
the symptoms. Sometimes a painful bone lesion is thought to be a
"muscle pull" or a "sprain" and strong pain medicines
are prescribed, allowing the patient to continue to tolerate very severe
pain before the true nature of the problem is discovered. Systemic symptoms
may also occur, such as hypercalcemia.
Breast cancer metastasis most commonly affects the spine, ribs, pelvis,
and proximal long bones.
The lesions can often be blastic but may also appear purely lytic, with
poor margination, no matrix and cortical destruction. When you see
a woman over age 40 with a history of breast cancer and multiple bone
lesions, think metastatic breast cancer. However, just the fact
that the patient had cancer does not prove that the lesion you see in
the bone is from that cancer. Do not bypass a careful history, physical
exam, and complete workup just because the patient gives a history of
breast cancer. Other lesions such as compression fractures of the
spine and cysts from osteoarthritis can appear to be tumors. Also remember
that primary bone sarcomas such as osteosarcoma and chondrosarcoma can
occur in an adult female patient.
The average survival after the diagnosis of a breast cancer metastasis
to bone has dramatically improved to about 24 - 36 months. The bisphosphonate
class of drugs is likely to lead to more improvements in survival.
Breast cancer is the most common cause of pathological fractures, and
orthopaedic surgeons who treat this disease should keep their approach
to treatment up to date with current surgical practice. There is
virtually no role for curative surgery. Orthopedic stabilization
of weakened bones should be done promptly, before fractures can occur.
Delay in treatment is normally associated with increased risk of complications
or a less favorable outcome. Since survival may be prolonged,
surgical reconstructions should be carefully done and designed to last.
Patients with extensive or advanced disease should still receive complete
treatment according to their wishes and reasonable medical principles.
Orthopaedic stabilization of actual or impending pathological fractures
should not be withheld unless the patient cannot tolerate anaesthesia
or would definitely not be benefited by surgery. The pain relief from
stabilization of damaged bones may warrant surgical treatment even if
the patient cannot enjoy a functional benefit, such as increased walking
ability.
|
|
 |